Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.

16 April 2026

Cytokine Release Symptoms rather than Syndromes: A call for Granular Reporting of Cytokine Related Adverse Events in Clinical Trials

01 April 2026

Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

01 April 2026

The Human Male Mammary Gland has Similar Epithelial Populations to Female but Distinct Composition and Transcriptional Properties.

31 March 2026

Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.

31 March 2026

The cost-effectiveness of tumour-infiltrating lymphocyte cell therapy for advanced melanoma: a systematic review.

20 March 2026

ASO Visual Abstract: The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC-A UK Single-Centre Experience and the Implications for Surgical Management.

19 March 2026

The Role of Cemiplimab in Treating Locally Advanced Cutaneous SCC: A UK Single-Centre Experience and the Implications for Surgical Management.

19 March 2026

INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

16 March 2026

Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.

12 March 2026

Tumour specific HORMAD1 expression perturbs mitotic arrest and drives sensitivity to mitotic kinase inhibitors.

11 March 2026

Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy.

06 March 2026